Prime Movers Lab Fund I LP - 10 Nov 2021 Form 3 Insider Report for Vaxxinity, Inc.

Role: 10%+ Owner
Signature: Prime Movers Lab Fund I LP /s/ Jon Layman, Authorized Person
Issuer symbol: VAXX on OTC
Transactions as of: 10 Nov 2021
Net transactions value: $0
Form type: 3
Filing time: 10 Nov 2021, 15:50:31 UTC
Previous filing: 16 Aug 2021
Next filing: 15 Nov 2021
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	VAXX	Series A preferred stock							10 Nov 2021	Class A common stock	3,570,201		See footnote	F1, F2, F11
holding	VAXX	Series A preferred stock							10 Nov 2021	Class A common stock	1,341,050		See footnote	F3, F4, F11
holding	VAXX	Series A preferred stock							10 Nov 2021	Class A common stock	2,361,626		See footnote	F5, F6, F11
holding	VAXX	Series B preferred stock							10 Nov 2021	Class A common stock	5,625,000		See footnote	F7, F8, F11
holding	VAXX	Series A preferred stock							10 Nov 2021	Class A common stock	15,152,627		Direct	F9, F10, F11

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The 3,570,201 shares of Series A preferred stock will convert into 2,294,473 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock.
F2	Held by COVAXX PML SPV 1 LP ("PML SPV 1"). Prime Movers Lab GP I LLC ("PML GP I") is the general partner of Prime Movers Lab Fund I LP ("PML") and PML SPV 1.
F3	The 1,341,050 shares of Series A preferred stock will convert into 861,857 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock.
F4	Held by COVAXX PML SPV 2 LP ("PML SPV 2"). Prime Movers Lab GP II LLC ("PML GP II") is the general partner of PML SPV 2.
F5	The 2,361,626 shares of Series A preferred stock will convert into 1,517,754 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock.
F6	Held by COVAXX PML SPV 3 LP ("PML SPV 3"). PML GP II is the general partner of PML SPV 3.
F7	The 5,625,000 shares of Series B preferred stock will convert into 3,615,038 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series B preferred stock.
F8	Held by Prime Movers Growth Fund 1 LP ("PMG"). Prime Movers Growth GP I LLC ("PMG GP") is the general partner of PMG.
F9	The 15,152,627 shares of Series A preferred stock will convert into 9,738,192 shares of Class A common stock automatically upon closing of the initial public offering based on a conversion rate of approximately 0.643 shares of Class A common stock for each share of Series A preferred stock.
F10	Held by PML. PML GP I is the general partner of PML.
F11	Dakin Sloss is the manager of PML GP I, PML GP II and PMG GP, and may be deemed to beneficially own the securities held by PML, PMG, PML SPV 1, PML SPV 2 and PML SPV 3. Mr. Sloss disclaims any beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein.